Landos Biopharma, Inc. Quarterly Accrued Liabilities, Current in USD from Q4 2020 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Landos Biopharma, Inc. quarterly Accrued Liabilities, Current history and growth rate from Q4 2020 to Q1 2024.
  • Landos Biopharma, Inc. Accrued Liabilities, Current for the quarter ending March 31, 2024 was $5.18M, a 178% increase year-over-year.
Accrued Liabilities, Current, Quarterly (USD)
Accrued Liabilities, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 $5.18M +$3.32M +178% Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $4.87M +$2.19M +81.4% Dec 31, 2023 10-Q 2024-05-09
Q3 2023 $4.43M +$2.16M +95.1% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $1.99M +$187K +10.4% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $1.86M -$3.84M -67.4% Mar 31, 2023 10-Q 2023-05-12
Q4 2022 $2.69M -$1.02M -27.4% Dec 31, 2022 10-K 2024-03-21
Q3 2022 $2.27M +$1.55M +213% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $1.8M +$209K +13.1% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $5.7M +$5.34M +1467% Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $3.7M +$1.76M +91% Dec 31, 2021 10-K 2023-03-23
Q3 2021 $726K Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $1.59M Jun 30, 2021 10-Q 2021-07-29
Q1 2021 $364K Mar 31, 2021 10-Q 2021-05-17
Q4 2020 $1.94M Dec 31, 2020 10-K 2022-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.